A Dynamic oral cancer field: Unraveling the underlying biology and its clinical implication

American Journal of Surgical Pathology

Volumn 33, Issue 11, 2009, Pages 1732-1738

  Tsui, Ivy F L ^a   Garnis, Cathie ^a   Poh, Catherine F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Clonality; Direct fluorescence visualization; Field cancerization; Oral cancer

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; CHROMOSOME LOSS; CONTROLLED STUDY; GENOME; HUMAN; HUMAN TISSUE; MALE; MOLECULAR CLONING; MOUTH CARCINOMA; MOUTH CAVITY; ORAL BIOPSY;

ANEUPLOIDY; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FLUORESCENCE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIGHT; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; TONGUE NEOPLASMS;

EID: 70350458819     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181b669c2     Document Type: Article

References (42)

1. Axell T, Pindborg JJ, Smith CJ, et al. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996;25:49-54.
2. Baldwin C, Garnis C, Zhang L, et al. Multiple microalterations detected at high frequency in oral cancer. Cancer Res. 2005;65: 7561-7567.
3. Batsakis JG, Suarez P, el-Naggar AK. Proliferative verrucous leukoplakia and its related lesions. Oral Oncol. 1999;35:354-359.
4. Bedi GC, Westra WH, Gabrielson E, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res. 1996;56:2484-2487.
5. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-1730.
6. Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist. 2005;10:493-500.
7. Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol. 2005;15:113-120.
8. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:429-435.
9. Buys TP, Aviel-Ronen S, Waddell TK, et al. Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma. J Thorac Oncol. 2009;4:227-239.
10. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996;56:2488-2492.
11. Chi B, deLeeuw RJ, Coe BP, et al. MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics. 2008;9:243.
12. Coe BP, Ylstra B, Carvalho B, et al. Resolving the resolution of array CGH. Genomics. 2007;89:647-653.
13. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25: 3766-3773.
14. Escher A, Piotet E, Waridel F, et al. p53 mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2009;266:547-551.
15. Fabricius EM, Gurr U, Wildner GP. Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head-and-neck. Anal Cell Pathol. 2002;24:25-39.
16. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck. 2003;25:67-73.
17. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet. 2004;36:299-303.
18. Jong K, Marchiori E, Meijer G, et al. Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics. 2004;20:3636-3637.
19. Khojasteh M, Lam WL, Ward RK, et al. A stepwise framework for the normalization of array CGH data. BMC Bioinformatics. 2005; 6:274.
20. Koch WM, Boyle JO, Mao L, et al. p53 gene mutations as markers of tumor spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg. 1994;120:943-947.
21. Lane PM, Gilhuly T, Whitehead P, et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt. 2006; 11:024006.
22. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79:321-329.
23. Partridge M, Pateromichelakis S, Phillips E, et al. Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res. 2001;7:1860-1866.
24. Pateromichelakis S, Farahani M, Phillips E, et al. Molecular analysis of paired tumours: time to start treating the field. Oral Oncol. 2005;41:916-926.
25. Poh CF, Zhang L, Anderson DW, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res. 2006;12:6716-6722.
26. Poh CF, Ng SP, Williams PM, et al. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck. 2007;29:71-76.
27. Poh CF, MacAulay CE, Zhang L, et al. Tracing the ''at-risk'' oral mucosa field with autofluorescence: steps toward clinical impact. Cancer Prev Res (Phila Pa). 2009;2:401-404.
28. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila Pa). 2009;2:423-431.
29. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357-362.
30. Rosin MP, Lam WL, Poh C, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 2002;62:6447-6450.
31. Rosin MP, Poh CF, Guillard M, et al. Visualization and other emerging technologies as change makers for oral cancer prevention. Ann N Y Acad Sci. 2007;1098:167-183.
32. Schepman KP, van der Waal I. A proposal for a classification and staging system for oral leukoplakia: a preliminary study. Eur J Cancer B Oral Oncol. 1995;31B:396-398.
33. Scholes AG, Woolgar JA, Boyle MA, et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res. 1998;58:2003-2006.
34. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:519-529.
35. Silverman S, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984; 53:563-568.
36. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multi-centric origin. Cancer. 1953;6:963-968.
37. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10:3607-3613.
38. Tsui IF, Rosin MP, Zhang L, et al. Multiple aberrations of chromosome 3p detected in oral premalignant lesions. Cancer Prev Res (Phila Pa). 2008;1:424-429.
39. van Houten VM, Leemans CR, Kummer JA, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res. 2004;10:3614-3620.
40. Worsham MJ, Wolman SR, Carey TE, et al. Common clonal origin of synchronous primary head and neck squamous cell carcinomas: analysis by tumor karyotypes and fluorescence in situ hybridization. Hum Pathol. 1995;26:251-261.
41. Zhang L, Michelsen C, Cheng X, et al. Molecular analysis of oral lichen planus. A premalignant lesion? Am J Pathol. 1997;151:323-327.
42. Zhang L, Williams M, Poh CF, et al. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res. 2005;65:8017-8021.